BiomX provided a program update regarding its BX004 development, including new FDA feedback that could expand its development pathways. This is a positive development for the company, suggesting progress in its regulatory interactions and potential for broader application of its therapeutic. The clarification of issues related to a third-party nebulizer and additional FDA requests indicate an ongoing, albeit complex, regulatory process. For investors in the biopharmaceutical sector, such updates are crucial for evaluating the company’s pipeline and future potential. The ability to navigate FDA feedback effectively is a key determinant of success. This is a ‘healthcare’ story.